Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D
5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics
Sitges M, Boluda B, Garrido A, Morgades M, Granada I, Barragan E, Arnan M, Serrano J, Tormo M, Miguel Bergua J, Colorado M, Salamero O, Esteve J, Benavente C, Pérez-Encinas M, Coll R, Martí-Tutusaus JM, Brunet S, Sierra J, Ángel Sanz M, Montesinos P, Ribera JM, Vives S
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols
Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Montesinos P, Barba P, Diaz-Beya M, Hermosin L, Maluquer C, Gonzalez-Campos J, Bernal T, Arriaga MS, Zamora L, Pratcorona M, Martino R, Larrayoz MJ, Artola T, Torrent A, Vall-Llovera F, Tormo M, Gil C, Novo A, Martinez-Sanchez P, Ribera J, Queipo MP, Gonzalez-Martinez T, Cabrero M, Cladera A, Cervera J, Orfao A, Ribera JM, Genesca E
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.
